Home  »  Business   »  AbCellera Biologics Inc. (ABCL) Stock Faces 10.35%...

AbCellera Biologics Inc. (ABCL) Stock Faces 10.35% Weekly Volatility

The stock of AbCellera Biologics Inc. (ABCL) has gone up by 18.12% for the week, with a 2.52% rise in the past month and a -17.44% drop in the past quarter. The volatility ratio for the week is 10.35%, and the volatility levels for the past 30 days are 6.38% for ABCL. The simple moving average for the past 20 days is 11.00% for ABCL’s stock, with a -29.49% simple moving average for the past 200 days.

Is It Worth Investing in AbCellera Biologics Inc. (NASDAQ: ABCL) Right Now?

Analysts have differing opinions on the stock, with 10 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


The average price point forecasted by analysts for AbCellera Biologics Inc. (ABCL) is $26.33, which is $19.42 above the current market price. The public float for ABCL is 203.83M, and currently, short sellers hold a 13.06% ratio of that floaft. The average trading volume of ABCL on May 26, 2023 was 1.92M shares.

ABCL) stock’s latest price update

The stock price of AbCellera Biologics Inc. (NASDAQ: ABCL) has plunged by -1.57 when compared to previous closing price of 7.02, but the company has seen a 18.12% gain in its stock price over the last five trading sessions. Barron’s reported on 09/17/21 that FDA’s Call on Lilly’s Covid Drug Is Lifting a Partner’s Beaten-Down Stock

ABCL Trading at 0.37% from the 50-Day Moving Average

After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.84% of loss for the given period.

Volatility was left at 6.38%, however, over the last 30 days, the volatility rate increased by 10.35%, as shares surge +4.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.00% lower at present.

During the last 5 trading sessions, ABCL rose by +18.12%, which changed the moving average for the period of 200-days by -37.80% in comparison to the 20-day moving average, which settled at $6.24. In addition, AbCellera Biologics Inc. saw -31.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ABCL starting from Thermopylae Holdings Ltd., who purchase 85,102 shares at the price of $10.10 back on Dec 16. After this action, Thermopylae Holdings Ltd. now owns 55,859,493 shares of AbCellera Biologics Inc., valued at $859,249 using the latest closing price.

Thermopylae Holdings Ltd., the 10% Owner of AbCellera Biologics Inc., purchase 200,000 shares at $11.46 during a trade that took place back on Aug 19, which means that Thermopylae Holdings Ltd. is holding 55,844,391 shares at $2,292,460 based on the most recent closing price.

Stock Fundamentals for ABCL

Current profitability levels for the company are sitting at:

  • +58.29 for the present operating margin

The net margin for AbCellera Biologics Inc. stands at +32.66. The total capital return value is set at 23.76, while invested capital returns managed to touch 13.37. Equity return is now at value -4.10, with -3.20 for asset returns.

Based on AbCellera Biologics Inc. (ABCL), the company’s capital structure generated 6.67 points at debt to equity in total, while total debt to capital is 6.25. Total debt to assets is 5.34, with long-term debt to equity ratio resting at 6.22. Finally, the long-term debt to capital ratio is 5.83.

When we switch over and look at the enterprise to sales, we see a ratio of 6.60, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 3.49 and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.67.


In a nutshell, AbCellera Biologics Inc. (ABCL) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.